Professor John Studd comments on what Adeola Olaitan had to say about men’s role in cervical cancer.

Read Full Post »

Consultant Gynaecologist Adeola Olaitan comments on Pharma Times reports that FDA staff like the look of Cervarix as well as Gardasil for men.

Read Full Post »

On Wednesday 24 June, it was announced that the Independent Advisory Committee on Cervical Cancer Screening (ACCS) recommended that the NHS not lower the screening age from 25 to 20

Read Full Post »

Fear plays a significant role in whether women decide to go for cancer screening according to a study published in the Journal of Advanced Nursing.

Read Full Post »

The Department of Health has announced a new drive to ensure GPs spot cervical cancer symptoms earlier in young women and refer patients correctly

Read Full Post »

A piece in Health Care Republic says that combining HPV testing with the current method of routine liquid-based cytology (LBC) screening does not appear to increase the detection of cervical cancer.

Read Full Post »

Zetiq Technologies, a subsidiary of Bio-Light, has successfully completed the first arm of its cervical cancer clinical trial, aimed at identifying and diagnosing cervical cancer in biopsies.

Read Full Post »

A new vaccine to prevent cervical cancer has shown promising responses in animals according to a paper published in the Journal of the National Cancer Institute. The vaccine, which would protect against many different types of HPV, has had robust antibody responses

Read Full Post »

It is encouraging that Cervarix® is found to generate a good immunogenic response but it is important to recognise that these results do not mean that Gardasil® is inferior to Cervarix® in protecting women against cervical cancer.

Read Full Post »

GSK’s cervical cancer vaccine, Cervarix®, is superior to Gardasil® in generating a significantly greater antibody response at seven months in women aged 18-45 against the two main cancer causing human papillomavirus (HPV) subtypes 16 & 18.

Read Full Post »